Search results for " Drug"

showing 10 items of 3138 documents

Strategies against nonsense: oxadiazoles as translational readthrough-inducing drugs (TRIDs)

2019

This review focuses on the use of oxadiazoles as translational readthrough-inducing drugs (TRIDs) to rescue the functional full-length protein expression in mendelian genetic diseases caused by nonsense mutations. These mutations in specific genes generate premature termination codons (PTCs) responsible for the translation of truncated proteins. After a brief introduction on nonsense mutations and their pathological effects, the features of various classes of TRIDs will be described discussing differences or similarities in their mechanisms of action. Strategies to correct the PTCs will be presented, particularly focusing on a new class of Ataluren-like oxadiazole derivatives in comparison …

0301 basic medicinemedia_common.quotation_subjectNonsenseNonsense mutationRegulatorSettore BIO/11 - Biologia MolecolareReviewComputational biologyBiologyOxadiazoleCatalysiscystic fibrosislcsh:ChemistryInorganic Chemistry03 medical and health sciences0302 clinical medicineAtalurenTranslational readthrough inducing drugsPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologyGeneSpectroscopymedia_commonNonsense mutationOrganic ChemistryTranslational readthroughoxadiazolesPremature termination codonTranslation (biology)General MedicineSettore CHIM/06 - Chimica OrganicaSmall moleculeSettore CHIM/08 - Chimica FarmaceuticaTransmembrane proteinComputer Science ApplicationsSettore BIO/18 - Genetica030104 developmental biologyPharmaceutical Preparationslcsh:Biology (General)lcsh:QD1-999Codon NonsenseProtein Biosynthesis030220 oncology & carcinogenesisCystic fibrosi
researchProduct

Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA

2017

Jay Amin Hydroxamic Acid (JAHA; N8-ferrocenylN1-hydroxy-octanediamide) is a ferrocene-containing analogue of the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA). JAHA’s cytotoxic activity on MDA-MB231 triple negative breast cancer (TNBC) cells at 72 h has been previously demonstrated with an IC50 of 8.45 M. JAHA’s lethal effect was found linked to perturbations of cell cycle, mitochondrial activity, signal transduction and autophagy mechanisms. In order to glean novel insights on how MDA-MB231 breast cancer cells respond to the cytotoxic effect induced by JAHA, and to compare the biological effect with the related compound SAHA, we have employed a combination of…

0301 basic medicinemedicine.drug_classAntineoplastic AgentsTriple Negative Breast NeoplasmsBiologyHydroxamic AcidsToxicologyStructure-Activity Relationship03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansCytotoxic T cellFerrous CompoundsSettore BIO/06 - Anatomia Comparata E Citologiaskin and connective tissue diseasesVorinostatTriple-negative breast cancerVorinostatDose-Response Relationship DrugHistone deacetylase inhibitorComputational BiologyGeneral MedicineTriple Negative Breast NeoplasmsCell cycleHistone Deacetylase InhibitorsSettore BIO/18 - Genetica030104 developmental biologyBiochemistryCell culture030220 oncology & carcinogenesisCancer researchHistone deacetylaseJAHA Comet assay MDA-MB231 Histone Deacetylase InhibitorsDrug Screening Assays Antitumormedicine.drug
researchProduct

Prospecting for cytotoxic and antiprotozoal 4-aryl-4H-chromenes and 10-aryldihydropyrano[2,3-f]chromenes.

2018

Different studies reported that genetic predisposition or metabolic dysfunction are the risk factors for cancer. Infectious parasitic diseases were listed among factors that predispose to cancer. Because of the resemblance between the life cycle of cancer cells and some parasites, this study aimed to prepare pyran derivatives with cytotoxic and antiprotozoal potencies. Therefore, 7 chromenes, 10 pyranocoumarins, and an unexpected intermediate were obtained from a multi-reagent one-pot reaction. These compounds were evaluated for their cytotoxicity on sensitive and resistant leukemia cancer cells lines and against two protozoan parasites, namely Trypanosoma cruzi and Leishmania amazonensis a…

0301 basic medicinemedicine.drug_classAntiparasiticTHP-1 CellsTrypanosoma cruziAntiprotozoal AgentsPharmaceutical ScienceAntineoplastic AgentsApoptosisPharmacology03 medical and health sciencesStructure-Activity RelationshipParasitic Sensitivity TestsDrug DiscoverymedicineTumor Cells CulturedCytotoxic T cellHumansBenzopyransTrypanosoma cruziCytotoxicityAmastigoteCell ProliferationLeishmaniabiologyDose-Response Relationship DrugMolecular StructureChemistryCancerCell Cycle Checkpointsbiology.organism_classificationmedicine.disease030104 developmental biologyCancer cellAntiprotozoalDrug Screening Assays AntitumorArchiv der Pharmazie
researchProduct

E-beam crosslinked nanogels conjugated with monoclonal antibodies in targeting strategies

2017

Abstract Poly(N-vinyl pyrrolidone)-based-nanogels (NGs), produced by e-beam irradiation, are conjugated with monoclonal antibodies (mAb) for active targeting purposes. The uptake of immuno-functionalized nanogels is tested in an endothelial cell line, ECV304, using confocal and epifluorescence microscopy. Intracellular localization studies reveal a faster uptake of the immuno-nanogel conjugate with respect to the ‘bare’ nanogel. The specific internalization pathway of these immuno-nanogels is clarified by selective endocytosis inhibition experiments, flow cytometry and confocal microscopy. Active targeting ability is also verified by conjugating a monoclonal antibody which recognizes the αv…

0301 basic medicinemedicine.drug_classConfocalmedia_common.quotation_subjecthigh-energy irradiationClinical BiochemistryNG[object Object]02 engineering and technologyMonoclonal antibodyBiochemistryCell LineFlow cytometrylaw.invention03 medical and health sciencesConfocal microscopylawFluorescence microscopemedicineHumansInternalizationMolecular Biologymedia_commonradiation-engineeredDrug Carriersmedicine.diagnostic_testChemistrywound healing assay.antiβ3 integrin antibodyAntibodies MonoclonalPovidoneactive-targetingBiological Transport021001 nanoscience & nanotechnologyMolecular biologyNanostructures030104 developmental biologyTargeted drug deliverynanogelpoly(N-vinyl pyrrolidone)Biophysics0210 nano-technologyGelswound healing assayNanogelBiological Chemistry
researchProduct

Estrogenic activity of zearalenone, α-zearalenol and β-zearalenol assessed using the E-Screen assay in MCF-7 cells

2017

Mycotoxins, including zearalenone (ZEA), can occur worldwide in cereals. They can enter the food chain and cause several health disorders. ZEA and its derivatives (α-zearalenol, α-ZOL and β-zearalenol, β-ZOL) have structural analogy to estrogen, thus they can bind to estrogen receptors (ERs). In order to characterize the estrogenic activity of ZEA, α-ZOL and β-ZOL, the proliferation of ER-positive human breast cancer cells (MCF-7) exposed to these mycotoxins was measured. After exposure at levels ranging from 6.25 to 25 µM, cell proliferation was evaluated by using the E-Screen bioassay. In accordance with previous studies, our results show the estrogenic activity of ZEA, α-ZOL and β-ZOL in…

0301 basic medicinemedicine.drug_classHealth Toxicology and Mutagenesista1172Cell Culture TechniquesEstrogen receptorToxicology03 medical and health scienceschemistry.chemical_compoundmedicineBioassayHumansEstrogens Non-SteroidalMycotoxinZearalenoneCell ProliferationDose-Response Relationship DrugChemistryCell growthfungifood and beveragesMolecular biology3. Good health030104 developmental biologyMCF-7Receptors EstrogenEstrogenCancer cellMCF-7 CellsZearalenoneZeranolta1181Biological AssayProtein BindingToxicology Mechanisms and Methods
researchProduct

Bistacrines as potential antitrypanosomal agents

2017

Human African Trypanosomiasis (HAT) is caused by two subspecies of the genus Trypanosoma, namely Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. The disease is fatal if left untreated and therapy is limited due to only five non-adequate drugs currently available. In preliminary studies, dimeric tacrine derivatives were found to inhibit parasite growth with IC50-values in the nanomolar concentration range. This prompted the synthesis of a small, but smart library of monomeric and dimeric tacrine-type compounds and their evaluation of antiprotozoal activity. Rhodesain, a lysosomal cathepsin-L like cysteine protease of T. brucei rhodesiense is essential for parasite survival a…

0301 basic medicinemedicine.drug_classTrypanosoma brucei bruceiClinical BiochemistryPharmaceutical ScienceFlavoproteinBiochemistryCell LineMiceStructure-Activity Relationship03 medical and health sciencesParasitic Sensitivity TestsOxidoreductaseparasitic diseasesDrug DiscoverymedicineAnimalsAfrican trypanosomiasisMolecular BiologyCell Proliferationchemistry.chemical_classificationDose-Response Relationship DrugMolecular StructurebiologyChemistryOrganic ChemistryTrypanosoma brucei rhodesiensemedicine.diseasebiology.organism_classificationTrypanocidal AgentsCysteine proteaseTrypanosomiasis African030104 developmental biologyBiochemistryTacrineTacrineAntiprotozoalbiology.proteinMolecular MedicineProtozoamedicine.drugBioorganic & Medicinal Chemistry
researchProduct

Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

2020

AbstractBackgroundCurrently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors). The study aimed to assess the incidence of clinical events and death in this population.MethodsThis was a cohort study on PWH from the PRESTIGIO Registry with a documented 4DR virus. Burden of disease was defined as the occurrence of any new event including an AIDS-defining event (ADE) or non-AIDS-defining event (NADE) or death from any cause after 4DR evidence (baseline). Co…

0301 basic medicinemedicine.medical_specialty4-class drug resistance; AIDS-defining event; cancer; death; non-AIDS-defining event4-class drug resistancenon-AIDS-defining event.PopulationMajor ArticlesSettore MED/0703 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinedeathmedicinecancerCumulative incidenceAIDS-defining event030212 general & internal medicineeducationnon-AIDS-defining eventDisease burdeneducation.field_of_studyProportional hazards modelbusiness.industryIncidence (epidemiology)Hazard ratio030112 virologyAcademicSubjects/MED00290Infectious DiseasesOncologybusinessCohort study
researchProduct

Is it time to combine untargeted antifungal strategies to reach the goal of 'early' effective treatment?

2016

A recently published retrospective study by Posteraro et al. [1] investigated the use of (1–3)-β-D-glucan (BDG) as a strategy for antifungal drug administration in patients at high risk of candidemia. The strategy consisted of the administration of antifungals (anidulafungin in most cases) to septic patients with a Candida score ≥ 3a nd a positive BDG result (≥80 pg/ml). This untargeted strategy led to better selection of patients, avoiding exposure to antifungals in approximately 73 % of patients with negative BDG results and leading to shortened treatment duration in another 20 % of patients. Untargeted antifungal treatments (including prophylaxis, pre-emptive and empiric approaches) are …

0301 basic medicinemedicine.medical_specialtyAntifungal Agents030106 microbiologyAntifungal drugCritical Care and Intensive Care Medicinelaw.inventionGoal03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumans; Treatment Outcome; Antifungal Agents; Goals; Critical Care and Intensive Care MedicineAntifungal AgentHumansStage (cooking)MED/41 - ANESTESIOLOGIAAdverse effectIntensive care medicineSurrogate endpointbusiness.industryIncidence (epidemiology)030208 emergency & critical care medicineRetrospective cohort studyTreatment OutcomeAnidulafunginbusinessGoalsmedicine.drugHumanCritical care (London, England)
researchProduct

What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects

2020

Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short…

0301 basic medicinemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsCoronavirus disease 2019 (COVID-19)Health PersonnelRetinal pathology / researchSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Context (language use)medicine.disease_causeRetinaAntimalarials03 medical and health sciences0302 clinical medicineRetinal DiseasesChloroquineInternal medicinePandemicmedicineHumansRETINARetina – medical therapiesCoronavirusPharmacologyOphthalmologistsSARS-CoV-2business.industryCOVID-19ChloroquineHydroxychloroquineGeneral MedicineSystemic drug retinal ToxicityTechniques of retinal examinationCOVID-19 Drug TreatmentCoronavirusClinical trialOphthalmology030104 developmental biologyCaregiversMedicina Preventiva y Salud Pública030221 ophthalmology & optometryHuman medicinebusinessHydroxychloroquinemedicine.drugEuropean journal of ophthalmology
researchProduct

Should we administer antifungal drugs before the diagnosis of invasive fungal infection in non-neutropenic critically ill patients?

2016

0301 basic medicinemedicine.medical_specialtyEmergency Medicine; Anesthesiology and Pain MedicineCritically illbusiness.industryAntifungal drugsAntifungal Treatment CORTEGIANI vs. DE ROSA: DEBATE First Round030106 microbiologysepsis fungal infectionNon neutropenic03 medical and health sciencesAnesthesiology and Pain Medicine0302 clinical medicineEmergency Medicinemedicine030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicinebusiness
researchProduct